Hot Features
プレミアム
登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。
Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, an... Vir Biotechnology Inc is a commercial-stage immunology company focused on treating and preventing infectious diseases. It has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA, through internal development, collaborations, and acquisitions. The company's pipeline consists of product candidates targeting hepatitis B virus, or HBV, influenza A, human immunodeficiency virus, or HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue and license revenue. 詳細を表示
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on...
– Designations aim to expedite the development and review of promising therapies for serious conditions with unmet medical needs – – Phase 3 ECLIPSE registrational program in chronic hepatitis...
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced it will host a virtual investor event to discuss initial data from the dual-masked Phase 1 T-cell engagers VIR-5818 targeting a variety of...
Vir Biotechnology Inc. (NASDAQ: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 7th Annual Evercore...
– Monthly tobevibart and elebsiran combination achieves rapid 100% virologic suppression at Week 24, sustained through Week 60 – – Undetectable HDV RNA in 41% of participants at Week 24...
– Orphan designation in E.U. supports development of treatments for life-threatening or chronically debilitating conditions with significant unmet medical need – – Phase 2 SOLSTICE 24-week...
– 39% of participants with low baseline Hepatitis B surface antigen (HBsAg) achieved HBsAg loss with tobevibart + elebsiran, and 46% with tobevibart + elebsiran + pegylated interferon alfa – – No...
| 期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.035 | 0.475220638153 | 7.365 | 7.56 | 7.145 | 1398017 | 7.3514171 | CS |
| 4 | -0.41 | -5.24967989757 | 7.81 | 9.95 | 7.025 | 1477747 | 7.97301744 | CS |
| 12 | -0.1 | -1.33333333333 | 7.5 | 10.44 | 6.56 | 1277455 | 8.09704538 | CS |
| 26 | -1.65 | -18.2320441989 | 9.05 | 11 | 6.56 | 1024498 | 8.33722398 | CS |
| 52 | -2.87 | -27.9454722493 | 10.27 | 13.09 | 6.56 | 1067749 | 9.1891259 | CS |
| 156 | -33.72 | -82.0038910506 | 41.12 | 42.54 | 6.56 | 1144430 | 17.75897978 | CS |
| 260 | -5.43 | -42.3226812159 | 12.83 | 141.01 | 6.56 | 1162648 | 28.09768268 | CS |
Monksdream
4日前
DewDiligence
2月前
Monksdream
2月前
TheFinalCD
5月前
DewDiligence
5月前
Monksdream
5月前
Monksdream
6月前
DewDiligence
7月前
DewDiligence
8月前
Monksdream
8月前
DewDiligence
8月前
Monksdream
8月前
DewDiligence
8月前
DewDiligence
10月前
DewDiligence
10月前
DewDiligence
10月前
DewDiligence
10月前
DewDiligence
10月前
DewDiligence
12月前
DewDiligence
1年前
harry crumb
1年前
DewDiligence
1年前
DewDiligence
2年前
DewDiligence
2年前
DewDiligence
3年前
DewDiligence
3年前
DewDiligence
3年前
DewDiligence
3年前
DewDiligence
3年前
rwwest
3年前
DewDiligence
3年前
DewDiligence
3年前
HokieHead
3年前
HokieHead
3年前
DewDiligence
3年前
DewDiligence
4年前
level42
4年前
interloper
4年前
dealerschool2006
4年前
rtrstock
4年前
CatBirdSeat
4年前
rtrstock
4年前
Srhogan1984
4年前
ClayTrader
4年前
Srhogan1984
4年前
DewDiligence
4年前
DewDiligence
4年前
DewDiligence
4年前
DewDiligence
4年前
Srhogan1984
4年前
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約
